EpiVax, Inc.
http://epivax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EpiVax, Inc.
Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention
Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.
Coronavirus Update: Inside Moderna's Deal With The US
Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
BioNotebook: One deal ends for Vanda, Novartis; five new agreements begin
Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools